As of 2025-04-26, the Relative Valuation of Cardiff Oncology Inc (CRDF) is (16.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.88 USD, the upside of Cardiff Oncology Inc based on Relative Valuation is -672.7%.
The range of the Relative Valuation is (13.18) - (18.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.3x - 32.5x | 25.9x |
| Forward P/E multiples | 17.3x - 27.5x | 22.4x |
| Fair Price | (13.18) - (18.78) | (16.49) |
| Upside | -557.7% - -752.1% | -672.7% |
| Date | P/E |
| 2025-04-25 | -4.22 |
| 2025-04-24 | -4.25 |
| 2025-04-23 | -4.30 |
| 2025-04-22 | -4.47 |
| 2025-04-21 | -4.13 |
| 2025-04-17 | -4.17 |
| 2025-04-16 | -4.11 |
| 2025-04-15 | -4.30 |
| 2025-04-14 | -4.09 |
| 2025-04-11 | -3.62 |
| 2025-04-10 | -3.48 |
| 2025-04-09 | -3.82 |
| 2025-04-08 | -3.73 |
| 2025-04-07 | -3.94 |
| 2025-04-04 | -4.03 |
| 2025-04-03 | -4.20 |
| 2025-04-02 | -4.41 |
| 2025-04-01 | -4.48 |
| 2025-03-31 | -4.60 |
| 2025-03-28 | -4.82 |
| 2025-03-27 | -5.04 |
| 2025-03-26 | -5.18 |
| 2025-03-25 | -5.56 |
| 2025-03-24 | -5.55 |
| 2025-03-21 | -5.49 |
| 2025-03-20 | -5.51 |
| 2025-03-19 | -5.62 |
| 2025-03-18 | -5.55 |
| 2025-03-17 | -5.93 |
| 2025-03-14 | -5.86 |
| 2025-03-13 | -5.78 |
| 2025-03-12 | -6.08 |
| 2025-03-11 | -5.24 |
| 2025-03-10 | -5.62 |
| 2025-03-07 | -5.64 |
| 2025-03-06 | -5.68 |
| 2025-03-05 | -6.25 |
| 2025-03-04 | -5.47 |
| 2025-03-03 | -5.59 |
| 2025-02-28 | -6.21 |
| 2025-02-27 | -5.94 |
| 2025-02-26 | -6.53 |
| 2025-02-25 | -6.19 |
| 2025-02-24 | -6.68 |
| 2025-02-21 | -6.95 |
| 2025-02-20 | -6.88 |
| 2025-02-19 | -7.00 |
| 2025-02-18 | -6.21 |
| 2025-02-14 | -6.28 |
| 2025-02-13 | -6.08 |